4W5S

Tankyrase in complex with compound


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.8 Å
  • R-Value Free: 0.263 
  • R-Value Work: 0.197 

wwPDB Validation 3D Report Full Report


This is version 1.0 of the entry. See complete history

Literature

Pyrimidinone nicotinamide mimetics as selective tankyrase and wnt pathway inhibitors suitable for in vivo pharmacology.

Johannes, J.W.Almeida, L.Barlaam, B.Boriack-Sjodin, P.A.Casella, R.Croft, R.A.Dishington, A.P.Gingipalli, L.Gu, C.Hawkins, J.L.Holmes, J.L.Howard, T.Huang, J.Ioannidis, S.Kazmirski, S.Lamb, M.L.McGuire, T.M.Moore, J.E.Ogg, D.Patel, A.Pike, K.G.Pontz, T.Robb, G.R.Su, N.Wang, H.Wu, X.Zhang, H.J.Zhang, Y.Zheng, X.Wang, T.

(2015) Acs Med.Chem.Lett. 6: 254-259

  • DOI: 10.1021/ml5003663
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • The canonical Wnt pathway plays an important role in embryonic development, adult tissue homeostasis, and cancer. Germline mutations of several Wnt pathway components, such as Axin, APC, and ß-catenin, can lead to oncogenesis. Inhibition of the poly( ...

    The canonical Wnt pathway plays an important role in embryonic development, adult tissue homeostasis, and cancer. Germline mutations of several Wnt pathway components, such as Axin, APC, and ß-catenin, can lead to oncogenesis. Inhibition of the poly(ADP-ribose) polymerase (PARP) catalytic domain of the tankyrases (TNKS1 and TNKS2) is known to inhibit the Wnt pathway via increased stabilization of Axin. In order to explore the consequences of tankyrase and Wnt pathway inhibition in preclinical models of cancer and its impact on normal tissue, we sought a small molecule inhibitor of TNKS1/2 with suitable physicochemical properties and pharmacokinetics for hypothesis testing in vivo. Starting from a 2-phenyl quinazolinone hit (compound 1), we discovered the pyrrolopyrimidinone compound 25 (AZ6102), which is a potent TNKS1/2 inhibitor that has 100-fold selectivity against other PARP family enzymes and shows 5 nM Wnt pathway inhibition in DLD-1 cells. Moreover, compound 25 can be formulated well in a clinically relevant intravenous solution at 20 mg/mL, has demonstrated good pharmacokinetics in preclinical species, and shows low Caco2 efflux to avoid possible tumor resistance mechanisms.


    Organizational Affiliation

    AstraZeneca R&D Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Tankyrase-1
A
211Homo sapiensMutation(s): 0 
Gene Names: TNKS (PARP5A, PARPL, TIN1, TINF1, TNKS1)
EC: 2.4.2.30
Find proteins for O95271 (Homo sapiens)
Go to Gene View: TNKS
Go to UniProtKB:  O95271
Small Molecules
Ligands 3 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
ZN
Query on ZN

Download SDF File 
Download CCD File 
A
ZINC ION
Zn
PTFCDOFLOPIGGS-UHFFFAOYSA-N
 Ligand Interaction
3J1
Query on 3J1

Download SDF File 
Download CCD File 
A
8-(hydroxymethyl)-2-[4-(1-methyl-1H-pyrazol-4-yl)phenyl]quinazolin-4(3H)-one
C19 H16 N4 O2
QFGWEEXXBWEZBP-UHFFFAOYSA-N
 Ligand Interaction
GOL
Query on GOL

Download SDF File 
Download CCD File 
A
GLYCEROL
GLYCERIN; PROPANE-1,2,3-TRIOL
C3 H8 O3
PEDCQBHIVMGVHV-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.8 Å
  • R-Value Free: 0.263 
  • R-Value Work: 0.197 
  • Space Group: I 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 81.010α = 90.00
b = 81.930β = 90.00
c = 82.170γ = 90.00
Software Package:
Software NamePurpose
BUSTERrefinement

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2015-05-13
    Type: Initial release